Several studies have shown decreased adiponectin levels in patients with coronary heart disease [47,48], diabetes [49], and hypertension [50] compared to control subjects, thus conferring a protective role for adiponectin against the development and progression of insulin resistance, high blood pressure, and CVDs. Here, ADIPOQ is linked to diabetes mellitus.